Oncimmune (ONC) Competitors GBX 15.15 +0.05 (+0.33%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider Trades ONC vs. TRX, POLB, SBTX, COS, C4XD, DDDD, AREC, SAR, OKYO, and OBIShould you be buying Oncimmune stock or one of its competitors? The main competitors of Oncimmune include Tissue Regenix Group (TRX), Poolbeg Pharma (POLB), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Arecor Therapeutics (AREC), Sareum (SAR), OKYO Pharma (OKYO), and Ondine Biomedical (OBI). These companies are all part of the "biotechnology" industry. Oncimmune vs. Tissue Regenix Group Poolbeg Pharma SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Arecor Therapeutics Sareum OKYO Pharma Ondine Biomedical Tissue Regenix Group (LON:TRX) and Oncimmune (LON:ONC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Is TRX or ONC more profitable? Oncimmune has a net margin of 586.08% compared to Tissue Regenix Group's net margin of -3.46%. Tissue Regenix Group's return on equity of -3.31% beat Oncimmune's return on equity.Company Net Margins Return on Equity Return on Assets Tissue Regenix Group-3.46% -3.31% 0.50% Oncimmune 586.08%-760.96%-26.38% Does the media refer more to TRX or ONC? In the previous week, Oncimmune's average media sentiment score of 1.14 beat Tissue Regenix Group's score of 0.00 indicating that Oncimmune is being referred to more favorably in the news media. Company Overall Sentiment Tissue Regenix Group Neutral Oncimmune Positive Does the MarketBeat Community favor TRX or ONC? Tissue Regenix Group received 94 more outperform votes than Oncimmune when rated by MarketBeat users. Likewise, 69.53% of users gave Tissue Regenix Group an outperform vote while only 59.13% of users gave Oncimmune an outperform vote. CompanyUnderperformOutperformTissue Regenix GroupOutperform Votes16269.53% Underperform Votes7130.47% OncimmuneOutperform Votes6859.13% Underperform Votes4740.87% Which has more volatility & risk, TRX or ONC? Tissue Regenix Group has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Oncimmune has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Do insiders and institutionals have more ownership in TRX or ONC? 37.0% of Tissue Regenix Group shares are owned by institutional investors. Comparatively, 25.0% of Oncimmune shares are owned by institutional investors. 47.3% of Tissue Regenix Group shares are owned by company insiders. Comparatively, 31.0% of Oncimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, TRX or ONC? Tissue Regenix Group has higher revenue and earnings than Oncimmune. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTissue Regenix Group£31.80M1.25-£1.10M-£0.01-5,600.00Oncimmune£1.21M9.28-£3.14M-£0.03-505.00 SummaryTissue Regenix Group beats Oncimmune on 10 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Oncimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricOncimmuneBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£11.23M£139.23M£5.09B£1.42BDividend YieldN/A3.50%5.04%11.56%P/E Ratio-505.00329.11101.481,569.60Price / Sales9.2815,219.191,207.98219,445.82Price / Cash11.9611.9639.7133.65Price / BookN/A7.236.932.81Net Income-£3.14M-£18.56M£118.81M£157.07M7 Day Performance-0.37%0.03%-1.39%-0.63%1 Month Performance-4.11%8.10%-3.29%3.20%1 Year Performance-32.37%25.03%32.29%97.44% Oncimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOncimmuneN/AGBX 15.15+0.3%N/A-33.2%£11.23M£1.21M-505.0052Positive NewsTRXTissue Regenix GroupN/AGBX 56-5.1%N/A+4.7%£39.89M£31.80M-5,600.00120POLBPoolbeg PharmaN/AGBX 7.60flatN/A-17.4%£38MN/A-770.0012News CoveragePositive NewsSBTXSkinBioTherapeuticsN/AGBX 16-1.5%N/A-21.4%£36.17M£21,949.00-800.0011COSCollagen Solutions plc (COS.L)N/AGBX 6.63flatN/A+0.0%£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AGBX 12+27.3%N/A-4.2%£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AGBX 16.66flatN/A+0.0%£30.05M£718,000.00-1.08106ARECArecor TherapeuticsN/AGBX 76.50flatN/A-58.0%£28.89M£4.90M-262.5010SARSareumN/AGBX 26flatN/A-56.9%£28.07M£47,204.00-440.003,211OKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007Gap DownOBIOndine BiomedicalN/AGBX 8.13flatN/A-18.4%£22.53M£1.63M-270.83N/A Related Companies and Tools Related Companies TRX Alternatives POLB Alternatives SBTX Alternatives COS Alternatives C4XD Alternatives DDDD Alternatives AREC Alternatives SAR Alternatives OKYO Alternatives OBI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:ONC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONC Stock Alerts